Cardiac drug delivery
This article was originally published in The Gray Sheet
Executive Summary
Life Medical Sciences is researching the incorporation of an anti-atrial fibrillation drug into its Repel-CV adhesion barrier to prevent surgery-related atrial fibrillation, a complication common in about one-third of open-heart surgeries, the firm announces at the Rodman & Renshaw TechVest Global Healthcare Conference in London May 12. The drug would be implanted in the bioabsorbable Repel-CV film, which is attached to the surface of the heart and absorbed during surgery. The direct-delivery system would replace systematic drug therapy, possibly curtailing hospitalization time. Repel-CV is currently in a U.S. multi-center pivotal trial to be completed in 2005 (1"The Gray Sheet" Sept. 8, 2003, p. 20)...